Syndax Pharmaceuticals 12-Month Price Target Cut to $37.27
The headline reports a cut to the stock’s 12-month price target to $37.27, implying 125% upside.
The headline reports a cut to the stock’s 12-month price target to $37.27, implying 125% upside.